COMP <GO>
AGMB vs AUTL // RETURN ON INVESTED CAPITAL (ROIC)
AgomAb Therapeutics NV (NASDAQ) VS. Autolus Therapeutics plc (NASDAQ) • 15-METRIC TALLY: AGMB 0
— AUTL 2
■ METRIC PARITY
LAST: $6.72 (-10.28%) • MKT CAP: $368.9M
roic
—
LAST: $1.42 (-6.58%) • MKT CAP: $404.6M
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AGMB VS. AUTL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AGMB | AUTL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | -27.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.7 | 38.4 | -5.70 | AUTL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $368.9M | $404.6M | -$35.7M | AUTL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AGMB REV | AUTL REV | AGMB GROSS % | AUTL GROSS % | AGMB FCF | AUTL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $75.4M | — | -27.8% | — | -$302.6M |
| FY 2024 | — | $10.1M | — | -12.5% | — | -$228.3M |
| FY 2023 | — | $1.7M | — | — | — | -$145.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AGMB // BETA —
AUTL // BETA —